Isatuximab, a novel anti-CD38 monoclonal antibody in the treatment of multiple myeloma: efficacy and safety

The article discusses the place of CD38 antibodies in the treatment of multiple myeloma (MM). Special emphasis is put of isatuximab. In 2020, isatuximab in combination with pomalidomide and dexamethasone was approved in Russia for the treatment of adult patients with MM who have received at least tw...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Karina E. Zatolochina, Sergey K. Zyryanov, Elena A. Ushkalova
Formato: article
Lenguaje:RU
Publicado: IP Habib O.N. 2021
Materias:
Acceso en línea:https://doaj.org/article/25784a31084f4d508ceb6bc0d0ac9915
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares